uniQure N.V. (QURE )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol QURE
- Company uniQure N.V.
- Price $13.92
- Changes Percentage 5.22
- Change 0.69
- Day Low $13.33
- Day High $14.3
- Year High $19.18
- Year Low $3.73
- Market Cap $738,237,681
- Price Avg 50 EMA (D) $11.02
- Price Avg 200 EMA (D) $7.05
- Exchange NASDAQ
- Volume 781,363
- Average Volume 2,195,296
- Open $13.81
- Previous Close $13.23
- EPS -4.95
- PE -2.79
- Earnings Announcement 2025-02-24 12:05:00
- Shares Outstanding $53,437,400
Company brief: UNIQURE N.V. (QURE )
- Healthcare
- Biotechnology
- Mr. Matthew Craig Kapusta
- https://www.uniqure.com
- NL
- N/A
- 02-05-2014
- NL0010696654
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.